IS7472A - 1- eða 3-þía-bensónaftóasúlen sem hindrar fyrir æxlisdrepþáttar framleiðslu og milliefni til framleiðslu þeirra - Google Patents
1- eða 3-þía-bensónaftóasúlen sem hindrar fyrir æxlisdrepþáttar framleiðslu og milliefni til framleiðslu þeirraInfo
- Publication number
- IS7472A IS7472A IS7472A IS7472A IS7472A IS 7472 A IS7472 A IS 7472A IS 7472 A IS7472 A IS 7472A IS 7472 A IS7472 A IS 7472A IS 7472 A IS7472 A IS 7472A
- Authority
- IS
- Iceland
- Prior art keywords
- production
- benzonaphthoazulene
- intermediates
- necrosis factor
- tumor necrosis
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 239000000543 intermediate Substances 0.000 title abstract 2
- QJCMSTPFSQAMGS-UHFFFAOYSA-N 16-thiapentacyclo[12.8.0.02,11.03,8.015,19]docosa-1(22),2(11),3,5,7,9,12,14,18,20-decaene Chemical compound C1=CC2=CCSC2=C2C=CC3=CC=C(C=CC=C4)C4=C3C2=C1 QJCMSTPFSQAMGS-UHFFFAOYSA-N 0.000 title 1
- 230000006433 tumor necrosis factor production Effects 0.000 title 1
- 102000000589 Interleukin-1 Human genes 0.000 abstract 2
- 108010002352 Interleukin-1 Proteins 0.000 abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- UDEQOVGVLPGNGN-UHFFFAOYSA-N C12=CC=CC2=CC=CC2=C1C=CC1=CC=C(C=CC=C3)C3=C21 Chemical class C12=CC=CC2=CC=CC2=C1C=CC1=CC=C(C=CC=C3)C3=C21 UDEQOVGVLPGNGN-UHFFFAOYSA-N 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
- C07D333/80—Seven-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HR20020303A HRP20020303A8 (en) | 2002-04-10 | 2002-04-10 | Benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| PCT/HR2003/000014 WO2003084961A1 (en) | 2002-04-10 | 2003-04-09 | 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS7472A true IS7472A (is) | 2004-09-27 |
Family
ID=28686901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7472A IS7472A (is) | 2002-04-10 | 2004-09-27 | 1- eða 3-þía-bensónaftóasúlen sem hindrar fyrir æxlisdrepþáttar framleiðslu og milliefni til framleiðslu þeirra |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20050137249A1 (is) |
| EP (1) | EP1492795B1 (is) |
| JP (1) | JP2005526827A (is) |
| KR (1) | KR20050014806A (is) |
| CN (1) | CN1649876A (is) |
| AT (1) | ATE310005T1 (is) |
| AU (1) | AU2003259958A1 (is) |
| BR (1) | BR0309097A (is) |
| CA (1) | CA2481850A1 (is) |
| DE (1) | DE60302344T2 (is) |
| ES (1) | ES2253694T3 (is) |
| HR (1) | HRP20020303A8 (is) |
| IL (1) | IL164395A0 (is) |
| IS (1) | IS7472A (is) |
| MX (1) | MXPA04009872A (is) |
| NO (1) | NO20044508L (is) |
| NZ (1) | NZ535622A (is) |
| PL (1) | PL374005A1 (is) |
| RU (1) | RU2318827C2 (is) |
| SI (1) | SI1492795T1 (is) |
| UA (1) | UA78297C2 (is) |
| WO (1) | WO2003084961A1 (is) |
| YU (1) | YU88104A (is) |
| ZA (1) | ZA200408059B (is) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20020304B1 (en) * | 2002-04-10 | 2008-04-30 | GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. | 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof |
| HRP20030160A2 (en) * | 2003-03-06 | 2005-04-30 | Pliva-Istra�iva�ki institut d.o.o. | 1-thiadibenzoazulene derivatives and biological action thereof |
| HRP20030955A2 (en) * | 2003-11-21 | 2005-08-31 | Pliva-Istra�iva�ki institut d.o.o. | USE OF 1-OXADIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS |
| HRP20030954A2 (en) * | 2003-11-21 | 2005-08-31 | Pliva D.D. | USE OF 1-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS |
| HRP20040104A2 (en) * | 2004-01-30 | 2005-10-31 | Pliva-Istra�iva�ki institut d.o.o. | Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders |
| KR20120037913A (ko) * | 2009-07-28 | 2012-04-20 | 니폰 조키 세야쿠 가부시키가이샤 | 티아벤조아줄렌프로피온산 유도체의 제조법 |
| JP6177769B2 (ja) * | 2011-06-02 | 2017-08-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | シータデフェンシンによる炎症性プロテアーゼの遮断 |
| CN104163811A (zh) * | 2013-05-16 | 2014-11-26 | 重庆圣华曦药业股份有限公司 | 一种制备度洛西汀盐酸盐的新方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3711489A (en) * | 1971-03-31 | 1973-01-16 | Pfizer | Certain 8,9-dihydro(3,4,7,8)cycloocta(1,2-d)imidazoles |
| CA967573A (en) | 1972-12-22 | 1975-05-13 | Joseph G. Lombardino | Tetracyclic anti-inflammatory agents |
| US4198421A (en) * | 1978-11-30 | 1980-04-15 | E. I. Du Pont De Nemours And Company | Antiinflammatory 2-substituted-dibenzo[2,3:6,7]oxepino[4,5-d]imidazoles |
| HRP20000310A2 (en) | 2000-05-17 | 2002-02-28 | Pliva Farmaceutska Ind Dioniko | New dibenzoazulene compounds as tumor necrosis factor inhibitors |
-
2002
- 2002-04-10 HR HR20020303A patent/HRP20020303A8/xx not_active IP Right Cessation
-
2003
- 2003-04-09 YU YU88104A patent/YU88104A/sh unknown
- 2003-04-09 NZ NZ535622A patent/NZ535622A/xx unknown
- 2003-04-09 DE DE60302344T patent/DE60302344T2/de not_active Expired - Fee Related
- 2003-04-09 IL IL16439503A patent/IL164395A0/xx unknown
- 2003-04-09 BR BR0309097-3A patent/BR0309097A/pt not_active IP Right Cessation
- 2003-04-09 RU RU2004132866/04A patent/RU2318827C2/ru not_active IP Right Cessation
- 2003-04-09 ES ES03745847T patent/ES2253694T3/es not_active Expired - Lifetime
- 2003-04-09 AT AT03745847T patent/ATE310005T1/de not_active IP Right Cessation
- 2003-04-09 CN CNA038099578A patent/CN1649876A/zh active Pending
- 2003-04-09 CA CA002481850A patent/CA2481850A1/en not_active Abandoned
- 2003-04-09 PL PL03374005A patent/PL374005A1/xx not_active Application Discontinuation
- 2003-04-09 JP JP2003582158A patent/JP2005526827A/ja active Pending
- 2003-04-09 KR KR10-2004-7016269A patent/KR20050014806A/ko not_active Ceased
- 2003-04-09 EP EP03745847A patent/EP1492795B1/en not_active Expired - Lifetime
- 2003-04-09 US US10/510,867 patent/US20050137249A1/en not_active Abandoned
- 2003-04-09 AU AU2003259958A patent/AU2003259958A1/en not_active Abandoned
- 2003-04-09 WO PCT/HR2003/000014 patent/WO2003084961A1/en not_active Ceased
- 2003-04-09 SI SI200330152T patent/SI1492795T1/sl unknown
- 2003-04-09 MX MXPA04009872A patent/MXPA04009872A/es active IP Right Grant
- 2003-09-04 UA UA20041008543A patent/UA78297C2/uk unknown
-
2004
- 2004-09-27 IS IS7472A patent/IS7472A/is unknown
- 2004-10-06 ZA ZA200408059A patent/ZA200408059B/en unknown
- 2004-10-12 US US10/963,979 patent/US7262309B2/en not_active Expired - Fee Related
- 2004-10-21 NO NO20044508A patent/NO20044508L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20020303A2 (en) | 2003-10-31 |
| UA78297C2 (en) | 2007-03-15 |
| JP2005526827A (ja) | 2005-09-08 |
| CN1649876A (zh) | 2005-08-03 |
| YU88104A (sh) | 2006-08-17 |
| SI1492795T1 (sl) | 2006-04-30 |
| WO2003084961A1 (en) | 2003-10-16 |
| RU2004132866A (ru) | 2005-06-10 |
| EP1492795A1 (en) | 2005-01-05 |
| US7262309B2 (en) | 2007-08-28 |
| IL164395A0 (en) | 2005-12-18 |
| KR20050014806A (ko) | 2005-02-07 |
| CA2481850A1 (en) | 2003-10-16 |
| AU2003259958A1 (en) | 2003-10-20 |
| US20050137249A1 (en) | 2005-06-23 |
| ATE310005T1 (de) | 2005-12-15 |
| ES2253694T3 (es) | 2006-06-01 |
| PL374005A1 (en) | 2005-09-19 |
| ZA200408059B (en) | 2005-10-06 |
| MXPA04009872A (es) | 2005-08-16 |
| EP1492795B1 (en) | 2005-11-16 |
| HRP20020303B8 (en) | 2009-03-31 |
| HRP20020303A8 (en) | 2009-03-31 |
| DE60302344T2 (de) | 2006-07-27 |
| NZ535622A (en) | 2006-03-31 |
| RU2318827C2 (ru) | 2008-03-10 |
| DE60302344D1 (de) | 2005-12-22 |
| HRP20020303B1 (en) | 2007-05-31 |
| NO20044508L (no) | 2004-11-09 |
| BR0309097A (pt) | 2005-02-09 |
| US20050130964A1 (en) | 2005-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX368368B (es) | Compuestos de indol e indazol como un inhibidor de necrosis celular. | |
| AU2003224923A1 (en) | Heterocyclic amide derivatives as cytokine inhibitors | |
| NO20044508L (no) | 1-eller 3-tia-henzonaftoazulener som inhibitorer av tumornektrosefaktorproduksjon og mellomprodukter for fremstilling derav | |
| IS7474A (is) | 1-Þía-bensónaftóasúlen sem hindrar fyrir æxlisdrepþáttar framleiðslu og milliefni til framleiðslu þeirra | |
| IS7473A (is) | 1-Oxa-3-aza-díbensóasúlen sem hindrar fyrir æxlisdrepþáttar framleiðslu og milliefni til framleiðslu þeirra | |
| MY138550A (en) | Method for synthesis of perindopril and its pharmaceutically acceptable salts | |
| WO2003097649A3 (en) | 1-oxa-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof | |
| WO2003099823A3 (en) | 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | |
| ATE399156T1 (de) | Neue indol- oder benzimidazol-derivate | |
| MX2007002833A (es) | Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios. | |
| WO2003099822A3 (en) | 1,2-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof | |
| MY136288A (en) | New process for the synthesis of perindopril and its pharmaceutically acceptable salts | |
| EP1558285A4 (en) | PROCESS FOR REDUCING DEPRESSIONS BY INHIBITING THE EFFECT OF THE N-TYPE CALCIUM CHANNEL | |
| NO20060922L (no) | Ny fremgangsmate for syntesen av perindopril og dens farmasoytiske akseptable salter | |
| TW200716565A (en) | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |